Sedation of Remazolam Combined With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery

NCT ID: NCT06810843

Last Updated: 2025-07-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 390 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-31
• Study Completion Date: 2027-12-31

Brief Summary

Non-intubated Thoracoscopic surgery (NITS) is a newly emerging minimally invasive surgical technique in recent years . Compared with traditional intubation general anesthesia, it has the advantages of less trauma, faster recovery and fewer complications . This surgical method allows patients to perform under local anesthesia or regional block and moderate sedation, providing a physiologic ventilation method , reducing the intervention on the respiratory system and conducive to rapid postoperative recovery.

The importance of sedative drugs in non-intubated thoracoscopic surgery Successful implementation of non-intubated thoracoscopic surgery requires sound regional block, airway management, and rational use of intravenous sedation and analgesics . In addition, sedative drugs need to have less respiratory and circulatory inhibition and fewer side effects. Propofol, as the most commonly used sedative drug, has a high incidence of adverse reactions such as injection pain and respiratory and circulatory inhibition. A large number of meta-analyses and systematic reviews have compared the sedative effects of remazolam and propofol, proving that Remazolam, as a new sedative, has advantages such as short half-life, rapid onset, rapid recovery, and light respiratory and circulatory inhibition.Compared with traditional benzodiazepines, Remazolam has a shorter half-life, which is conducive to rapid postoperative wakeup and reduces the risk of discomfort and cognitive dysfunction in patients. In addition, remazolam has little influence on the respiratory system and is relatively stable on the circulatory system ，which is an ideal sedation option for non-intubated thoracoscopic surgery that retains spontaneous respiration. Afentanil mainly acts on μ opioid receptors , and its analgesic intensity is about 15 times that of morphine, which has the advantages of rapid onset, short duration of action, rapid recovery, high safety, and few adverse reactions . Afentanil has a short half-life , mild respiratory depression, low incidence of cough, postoperative nausea and vomiting . Remazolam combined with afentanil is widely used in various surgeries or examinations that preserve spontaneous breathing, such as gastroenteroscopy, ERCP, hysteroscopy, short-term plastic surgery and fiberbronchoscopy, and has shown the advantage of light respiratory circulation inhibition . We speculate that remazolam combined with afentanil may have certain advantages in non-intubated thoracoscopic surgery that retains spontaneous breathing. At present, the application of remazolam combined with afentanil in non-intubated thoracoscopic surgery is still lacking. The purpose of this study was to observe the safety and effectiveness of remazolam combined with afentanil in non-intubated thoracoscopic surgery, and to provide a better choice of sedation drugs for non-intubated thoracoscopic surgery.

Detailed Description

Research object Patients aged 18 years or older undergoing non-intubated thoracoscopic lung surgery 3.2 Sample size calculation According to the study of Goyal R etal., propofo-based sedation resulted in a decrease in oxygen saturation in nearly 43% of patients. Therefore, assuming a 15% reduction in anoxic events in the remazolam group, PASS-2021 software, comparison of two independent sample rates, bilateral Z test, 80% confidence, and a significant difference level of 0.05, we estimated that the sample size in each group in this study was 156 patients, and considering the 20% shedding rate, 195 patients were required in each group. A sample size of 390 cases is required.

3.3 Scheduling Standards 3.3.1 Inclusion criteria:

1. American Society of Anesthesiologists ASA Level I to III;

2. 18 years old ≤ age ≤80 years old;

3. Non-intubated thoracoscopic lung surgery under deep sedation;

4. 18kg/m2≤BMI≤30 kg/m2;

5. Voluntarily participate in the study and sign the informed consent. 3.3.2 Exclusion criteria:

(1) Pulmonary function examination showed moderate to severe ventilation or exchange impairment (FEV1< 60% of the predicted value, carbon monoxide diffusion < 60% of the predicted value); (2) Abnormal liver and kidney function (Child-Pugh grade liver function is grade B and grade C; Endogenous creatinine clearance ≤50mL/min, serum creatinine >178µmol/L or renal function test urea nitrogen >9mmol/L) (3) SpO2 < 95% before operation; (4) History of recovery from abnormal surgical anesthesia; (5) History of thoracic surgery or history of tuberculosis or systemic infection within one month; (6) Severe cardiovascular and cerebrovascular diseases (patients with severe cardiovascular and cerebrovascular diseases: high risk of hypertension, untreated coronary heart disease, valvular heart disease, previous myocardial infarction, cerebral infarction, cerebral thrombus, cerebral hemorrhage); (7) Take monoamine oxidase inhibitors or antidepressants within 15 days; (8) Chronic pain from long-term use of analgesics or psychotropic drugs, alcoholism; (9) Known drug allergy; (10) expected difficult airway; (11) Pregnant women or women giving birth; (12) Participation in other drug trials within three months or inability to communicate well with researchers.

3.3.3 Shedding cases After signing informed consent and screening qualified for clinical trial, the patients did not complete the full clinical trial visit. Such as adverse events, patient loss of follow-up, patients who were converted to general anesthesia during the operation for reasons other than severe hypoxia, patients who could not complete the evaluation after surgery, patients voluntarily withdrew informed consent, and emergency blinding was initiated.

3.4 Randomization and blind method Block randomization was employed. The randomization scheme was generated by the researchers using the website (www.random.org). Random number in a light-tight sealed envelope. In this study, patients meeting the inclusion/exclusion criteria will be randomized into the trial group (remazolam, group R) and the control group (propofol, group P) in a 1:1 ratio. Since propofol is colored and remazolam is colorless, the anesthesiologist performing the anesthesia is non-blind. Follow-up personnel and statisticians, patients and chest doctors were blind.

3.5 Specific research content BIS, electrocardiogram, SpO2, blood pressure, heart rate, open venous access, nasal catheter oxygen inhalation (3L/min) were monitored. Under the guidance of local anesthesia ultrasound, three paravertebral T4-5-6 points were blocked successively, and 0.25% ropivacaine 15ml was administered. After disinfection, the anesthetic plane was tested to be effective before cutting the skin, then intravenous medication was started. If the patient is in pain before the incision, the surgeon gives additional local anesthesia and then starts intravenous medication. Two anesthesiologists are in charge of the patient throughout the procedure. Afentanil (dose 10μg/kg, Yichang Renfu Pharmaceutical Co., LTD.), 3 minutes before sedative administration. Then, in the remazolam group, 0.3mg/kg remazolam (Yichang Renfu Pharmaceutical Co., LTD.) was administered for > 60 seconds. Sedation was maintained by continuous infusion of remazolam 0.2 to 1mg/kg/h and afentanil 0 to 1μg/kg/min. The propofol group was given 1.5 to 2mg/kg propofol, continued infusion of propofol 2 to 6 mg/kg/h and afentanil 0 to 1μg/kg/min to maintain sedation. The anesthesiologist maintained sedation at the target level, maintaining the Modified Observer Alertness/Sedation Scale (MOAA/S) between 1-2. For example, if the MOAA/ S is higher than 2 and the patient is still overreacting and cannot tolerate surgery, use 0.1mg/kg remazolam push or 0.5mg/kg propofol, respectively, as additional sedation. In addition, both groups were given 5μg/kg of afentanil for additional analgesia. After surgery, patients were transferred to the recovery room, where their HR, SpO2, NIBP, and MOAA/S were monitored. A modified Aldrete score was used to assess recovery. Patients are only allowed to return to the room if their Aldrete score is at least 9 and there are no obvious side effects such as nausea or dizziness.

Hypotension was defined as MAP<65 mmHg or a 20% decrease from baseline, while hypertension was defined as MAP>105 mmHg or a 20% increase from baseline. According to the American Heart Association, when hypotension or hypertension occurs, we take two blood pressure readings immediately to provide a more accurate blood pressure. Patients with hypotension and accelerated heart rate received a 4ug norepinephrine push injection, then titrated to BP and heart rate. In contrast, patients with hypotension and HR < 60 bpm received a push dose of 10 mg ephedrine, which was then titrated to blood pressure and heart rate. In hypertensive patients, 5 mg urapidil was administered and titrated to BP. If the heart rate drops to <45 bpm, atropine 0.25mg is injected intravenously and titrated to the heart rate. If heart rate >110 bpm, Esmolol (10 mg) is administered intravenously and titrated to heart rate.

Conditions

Pulmonary Nodule Cm

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Group-R

Afentanil (dose 10 μg/kg, Yichang Renfu Pharmaceutical Co., LTD.), 3 minutes before sedative administration. Then, in the remazolam group (group R), 0.3mg/kg remazolam (Yichang Renfu Pharmaceutical Co., LTD.) \> 60 seconds. Sedation was maintained by continuous infusion of remazolam 0.2 to 1 mg/kg/h and afentanil 0 to 1μg/kg/min.

Group Type: EXPERIMENTAL

Remazolam combined with afentanil for non-intubated thoracoscopic surgery

Intervention Type: DRUG

Remazolam combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,

Group-P

Propofol group (Group P) was given 1.5 to 2mg/kg propofol, continued infusion of propofol 2 to 6 mg/kg/h and afentanil 0 to 1μg/kg/min to maintain sedation. The anesthesiologist maintained sedation at the target level, maintaining the Modified Observer Alertness/Sedation Scale (MOAA/S) between 1-2.

Group Type: ACTIVE_COMPARATOR

Propofol combined with afentanil in non-intubated thoracoscopic surgery

Intervention Type: DRUG

Propofol combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,

Interventions

Remazolam combined with afentanil for non-intubated thoracoscopic surgery

Remazolam combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,

Intervention Type: DRUG

Propofol combined with afentanil in non-intubated thoracoscopic surgery

Propofol combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,

Intervention Type: DRUG

Other Intervention Names

Under the guidance of local anesthesia ultrasound, three paravertebral T4-5-6 points were blocked successively; Under the guidance of local anesthesia ultrasound, three paravertebral T4-5-6 points were blocked successively

Eligibility Criteria

Inclusion Criteria

• American Society of Anesthesiologists ASA Level I to III;
• 18 years-80 years old;
• Non-intubated thoracoscopic lung surgery under deep sedation;
• 18 kg/m2≤BMI≤30 kg/m2;
• Voluntarily participate in the study and sign the informed consent.

Exclusion Criteria

• Pulmonary function tests showed moderate to severe ventilation or exchange disorders (FEV1< 60% of the predicted value, carbon monoxide diffusion < 60% of the predicted value);
• Abnormal liver and kidney function (Child-Pugh grade liver function is grade B and grade C; Endogenous creatinine clearance ≤50mL/min, serum creatinine >178µmol/L or urea nitrogen >9mmol/L by renal function test);
• SpO2 < 95% before operation;
• History of recovery from abnormal surgical anesthesia;
• History of thoracic surgery or history of tuberculosis or systemic infection within one month;
• Severe cardiovascular and cerebrovascular diseases (patients with severe cardiovascular and cerebrovascular diseases:

High risk of hypertension, untreated coronary heart disease, valvular heart disease, previous myocardial infarction, cerebral infarction, cerebral thrombus, cerebral hemorrhage);

• Take monoamine oxidase inhibitors or antidepressants within 15 days;
• Chronic pain from long-term use of analgesics or psychotropic drugs, alcoholism;
• Known drug allergy;
• Expected difficult airway;
• Pregnant women or women giving birth;
• Participation in other drug trials within three months or inability to communicate well with researchers

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Qianfoshan Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jianbo Wu

chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

jian Bo Wu, PH.D

Role: STUDY_CHAIR

Shandong First Medical University

Locations

The First Affiliated Hospital of Shandong First Medical University（Qianfoshan Hospital, Shandong Province）

Jinan, , China

Countries

China

Central Contacts

jian bo Wu, PH.D

Role: CONTACT

jianbowu@126.com

18560083793

NA GUO

Role: CONTACT

xinzangbianshu@163.com

18615605135

Other Identifiers

YXLL-KY-2024(169)

Identifier Type: -

Identifier Source: org_study_id